

Fremont, CA

Verseon

Sale / Leaseback

Transwestern executed a sale-leaseback on behalf of Verseon, who used the sale proceeds to continue funding their clinical trials for a drug that prevents the formation of blood clots.

The \$34.7-million facility was encumbered by PACE financing and would be leased to an early-stage pharmaceutical company, which put the asset at risk.

To combat these challenges, Transwestern identified investors who were comfortable with the inherent risks of owning such a specialized facility, which created competition among potential investors.

Transwestern sourced a risk-tolerant investor who saw the value in partnering with Verseon and provided a purchase option, allowing Verseon to continue focusing on its lifesaving research. Helping you focus on what matters.